Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Gamelin Erick, holds the title of Chief Development Officer at Acrivon Therapeutics, Inc..
On 2026-11-17, the insider transacted 416 shares.The shares were transacted at a weighted average price of $1.45 per share, resulting in a total market-relevant value of $603.2.
Gamelin Erick (Chief Development Officer) sold $603 of $ACRV
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.